Collegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended March 2026, Collegium Pharmaceutical (COLL) reported revenue of $193.52 million, up 8.9% over the same period last year. EPS came in at $1.76, compared to $1.49 in the year-ago quarter.The reported revenue represents a surprise of +7.01% over the Zacks Consensus Estimate of $180.85 million. With the consensus EPS estimate being $1.42, the EPS surprise was +23.94%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Collegium Pharmaceutical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Total product revenues- Belbuca: $52.65 million versus $51.77 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +1.9% change.Total product revenues- Xtampza ER: $50.77 million versus the two-analyst average estimate of $46.86 million. The reported number represents a year-over-year change of +6.6%.Total product revenues- Jornay PM: $38.89 million versus $37.13 million estimated by two analysts on average.Total product revenues- Nucynta (Nucynta IR+Nucynta ER): $44.31 million versus $41.74 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -5.9% change.Total product revenues- Symproic: $4.19 million versus $3.37 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +49% change.View all Key Company Metrics for Collegium Pharmaceutical here>>>Shares of Collegium Pharmaceutical have returned +9.2% over the past month versus the Zacks S&P 500 composite's +11.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Beyond Nvidia: AI's Second Wave Is HereThe AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.See Stocks Now >>This article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks